AZALIA® - Bioequivalent to Cerazette®

  • Contains 75μg desogestrel and no oestrogen, exactly the same active ingredient as Cerazette®¹-²

 

  • AZALIA® is GMS Reimbursed

 

  • Oestrogen-free progestogen-only contraceptive pill¹

 

  • Indicated for the prevention of pregnancy in women who elect to use an oral contraceptive with no oestrogen¹

 

  • Inhibits ovulation and increases the viscosity of the cervical mucus¹

 

  • Reliable, highly effective and well tolerated oral contraceptive when taken correctly¹-⁴

 

  • AZALIA® has a Pearl Index of 0.4¹

 

  • Side effects associated with combined oral contraceptives may be reduced or ameliorated by taking an oestrogen-free pill such as AZALIA®⁴

 

  • In a clinical trial 85–87% of women indicated that they would continue to use 75μg desogestrel at the end of the trial⁴

 

  • AZALIA® has a 12-hour missed pill window¹

 

  • AZALIA® is taken continuously as a 28 day treatment regime¹

 

Change your desogestrel patients to Azalia® to save them money on their contraceptive prescription³
View pricing comparison with originator brand

AZALIA® is suitable for use in the following patient groups:⁵-⁶

  • Women of all ages including breast feeding women
  • Women with a BMI of ≥35 kg/m2
  • Women who smoke
  • Women who experience oestrogen-related side effects on COCs
  • Women who suffer from hypertension
  • Women with a family history of venous thromboembolism
  • Women with endometriosis
 

 



References

1. Azalia® SmPC
2. Cerazette® SmPC
    available at www.medicines.ie
3. MIMS Ireland (August 2017) 'Contraception' MPI Media Ltd, Dublin.
4. Ahrendt HJ, Karckt U, Pichl T, et al. The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: results from
two studies on oestrogen-related symptoms and dysmenorrhoea. Eur J Contracept Reprod Health Care 2007; 12(4): 354–361.
5. WHO Guidelines. Medical Eligibility Criteria for contraceptive use 2015 update.
6. Faculty of Sexual and Reproductive Health Care (FSRH). UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2016. London: FSRH, 2016.